Skip to main content

Table 1 Subject demographics and baseline characteristics

From: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Patient Characteristics AboBoNT-A (N = 253) OnaBoNT-A (N = 103) All Patients (N = 356)
Age in Years
 18 to 30 13 (5.1%) 4 (3.9%) 17 (4.8%)
 31 to 40 37 (14.6%) 9 (8.7%) 46 (12.9%)
 41 to 50 74 (29.2%) 18 (17.5%) 92 (25.8%)
 51 to 60 58 (22.9%) 36 (35%) 94 (26.4%)
 61 to 70 45 (17.8%) 26 (25.2%) 71 (19.9%)
  > 70 26 (10.3%) 10 (9.7%) 36 (10.1%)
Body Weight (kg), mean (SD) 72.7 (14.9) 73.7 (15.3) 73.0 (15.0)
Sex (n,%)
 Female 162 (64%) 69 (67%) 231 (64.9%)
 Male 91 (36%) 34 (33%) 125 (35.1%)
Previous Surgery (n,%)
 No 248 (98%) 100 (97.1%) 348 (97.8%)
 Yes 5 (2%) 3 (2.9%) 8 (2.2%)
Prior Treatment with BoNT-A (n,%)
 No 49 (19.4%) 7 (6.8%) 56 (15.7%)
 Yes 204 (80.6%) 96 (93.2%) 300 (84.3%)
Tremor (n,%)
 Absent 142 (56.1%) 41 (39.8%) 183 (51.4%)
 Present 111 (43.9%) 62 (60.2%) 173 (48.6%)
Predominant Component (n,%)
 Not Rotation 49 (19.4%) 38 (36.9%) 87 (24.4%)
 Rotation 204 (80.6%) 65 (63.1%) 269 (75.6%)
EMG at Baseline (n,%)
 No 151 (59.7%) 40 (38.8%) 191 (53.7%)
 Yes 102 (40.3%) 63 (61.2%) 165 (46.3%)
TWSTRS Scores at Baseline
 Total Score, mean (SD) 37.8 (9.4) 33.9 (11.1) 37.1 (10.2)
 Severity Subscale Score, mean (SD) 20.1 (3.5) 18.9 (3.4) 19.8 (3.5)
 Disability Subscale Score, mean (SD) 11.1 (5.3) 9.2 (6.0) 10.7 (5.6)
 Pain Subscale Score, mean (SD) 6.6 (4.7) 5.8 (4.9) 6.6 (4.8)
EQ-5D Utility Score at Baseline, mean (SD) 0.56 (0.03) 0.57 (0.03) 0.57 (0.03)
Total Injected Units of BoNT-A, mean (SD) 598.8 (231.9) 172.9 (66.5)
  1. SD Standard deviation; EMG electromyography; BoNT-A Botulinum Neurotoxin type A; TWSTRS Toronto Western Spasmodic Torticollis Rating Scale; EQ-5D EuroQol 5 Dimensions Questionnaire